CAR-T learning lab
Explore the components of an engineered T cell, compare a tumor with its baseline and control, and practice six evidence distinctions.
Change a number, test an idea, and say exactly what the result supports. This lab helps you practice reading claims about chimeric antigen receptor (CAR) T cells.
Before you start: A CAR helps a T cell recognize a chosen surface target. Ex vivo and in vivo engineering describe whether the cells receive their new instructions outside or inside the body. If those ideas are new, visit the linked concepts first.
Choose an activity
| Activity | Your task | Question to carry forward |
|---|---|---|
| The building blocks | Select the carrier, payload, CAR, added receptor and living cell. | What job does this component do, and what remains unresolved? |
| Read a graph | Change the starting, control and treated volumes. | Is the treated tumor smaller than the control, its own baseline, or both? |
| Check your understanding | Answer six questions and read the explanations. | Which claim is measured, and which next step is still untested? |
Take the activities in any order. Try an answer before revealing the reasoning. An incorrect answer is useful: it tells you which distinction to practice again.
Practice studio
The numbers are invented for practice. The illustration simplifies biology and is not experimental evidence. Your answers are not saved or sent anywhere.
Open the learning lab on its own if you would like more space. For a text version of the key reasoning, use Reading cell-therapy evidence.
Offline download: The original learning lab ZIP remains available. Unzip it and open the included HTML file in a browser.
The quiz calls one added receptor “MIMIC.” For this exercise, read that as a synthetic signaling component. Its question asks what increased cell counts establish; it does not demonstrate a program's clinical performance.
Start with this experiment
Leave the starting volume at 100, the control at 1,000, and the treated value at 300. The treated tumor is 70% smaller than the control, yet three times its own starting size. It grew more slowly; it did not shrink below baseline.
Now change the treated value to 30. It is below baseline, with measurable tumor remaining. Finally, try 0. A zero at one time point cannot tell you whether the response will last.
The graph uses hypothetical tumor volumes, not a clinical response rule. It cannot estimate a person's treatment outcome.
Explain it back
Complete this sentence: “The treated tumor is smaller than ___, but that does not yet establish ___.”
One possible answer is: “The treated tumor is smaller than the control, but that does not yet establish regression below its own baseline.” A different comparison may be correct when you change the inputs. Name your comparator each time.
Takeaway
A component, a cell count, a tumor measurement and a clinical benefit answer different questions. When you finish, return to the engineered-cell guide to place the evidence in the full development chain.
Sources and scope
Source-checked October 9, 2026; expert and learner review remain pending. The original lab and archive are preserved unchanged, including the lab's September 15, 2026 footer. The graph and quiz use conceptual scenarios, with no patient results or treatment recommendations.
- NCI: CAR T Cells—Engineering Patients' Immune Cells to Treat Their Cancers: receptor structure, target recognition and the challenges posed by solid tumors.
- Hunter et al., Science, 2025: in vivo engineering studied in human-cell samples, humanized mice and nonhuman primates. These are distinct evidence settings.
- Engelowski et al., Nature Communications, 2018: an experimental example of synthetic cytokine receptors transmitting signals. Component research does not establish a finished treatment's clinical benefit.